These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 38694909)

  • 1. Sotagliflozin versus dapagliflozin to improve outcome of patients with diabetes and worsening heart failure: a cost per outcome analysis.
    Zhang W; Yu M; Cheng G
    Front Pharmacol; 2024; 15():1373314. PubMed ID: 38694909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotagliflozin vs Dapagliflozin: A Systematic Review Comparing Cardiovascular Mortality.
    Iyer N; Hussein S; Singareddy S; Sn VP; Jaramillo AP; Yasir M; Nath TS
    Cureus; 2023 Sep; 15(9):e45525. PubMed ID: 37868384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin vs. sacubitril-valsartan for prevention of heart failure events in non-diabetic patients with reduced ejection fraction: a cost per outcome analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Eur J Prev Cardiol; 2021 Dec; 28(15):1665-1669. PubMed ID: 33624086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dapagliflozin Versus Empagliflozin on Cardiovascular Death in Patients with Heart Failure Across the Spectrum of Ejection Fraction: Cost per Outcome Analysis.
    Alnsasra H; Tsaban G; Solomon A; Khalil F; Aboalhasan E; Weinstein JM; Azuri J; Hammerman A; Arbel R
    Am J Cardiovasc Drugs; 2023 May; 23(3):323-328. PubMed ID: 37067768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotagliflozin: Efficacy, Safety, and Potential Therapeutic Applications in Heart Failure.
    Long A; Salvo M
    Ann Pharmacother; 2024 Sep; 58(9):935-946. PubMed ID: 38014844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparison of SGLT2 inhibitors in patients with established heart failure: evidence based on Bayesian methods.
    Chen HB; Yang YL; Meng RS; Liu XW
    ESC Heart Fail; 2023 Apr; 10(2):1231-1241. PubMed ID: 36702979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sotagliflozin on Early Mortality and Heart Failure-Related Events: A Post Hoc Analysis of SOLOIST-WHF.
    Pitt B; Bhatt DL; Szarek M; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Ezekowitz JA; Sun F; Davies MJ; Verma S; Kosiborod MN; Steg PG;
    JACC Heart Fail; 2023 Aug; 11(8 Pt 1):879-889. PubMed ID: 37558385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin
    Arbel R; Azab AN; Oberoi M; Aboalhasan E; Star A; Elhaj K; Khalil F; Alnsasra H
    Front Pharmacol; 2024; 15():1357673. PubMed ID: 38567348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Versus Sacubitril-Valsartan to Improve Outcomes of Patients with Reduced Ejection Fraction and Diabetes Mellitus.
    Hammerman A; Azuri J; Aboalhasan E; Arbel R
    Am J Cardiovasc Drugs; 2022 May; 22(3):325-331. PubMed ID: 34671945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Szarek M; Bhatt DL; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Banks P; Tesfaye E; Ezekowitz JA; Verma S; Pitt B;
    Ann Intern Med; 2021 Aug; 174(8):1065-1072. PubMed ID: 34152828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular benefits and safety of sotagliflozin in type 2 diabetes mellitus patients with heart failure or cardiovascular risk factors: a bayesian network meta-analysis.
    Li J; Zhu C; Liang J; Hu J; Liu H; Wang Z; Guan R; Chow J; Yan S; Li L; Ma F; Ma G
    Front Pharmacol; 2023; 14():1303694. PubMed ID: 38044937
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials.
    Duan XY; Liu SY; Yin DG
    Medicine (Baltimore); 2021 Jul; 100(30):e26431. PubMed ID: 34397684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sotagliflozin in Adults With Type 2 Diabetes in Relation to Baseline Hemoglobin A1c.
    Aggarwal R; Bhatt DL; Szarek M; Cannon CP; McGuire DK; Inzucchi SE; Lopes RD; Davies MJ; Banks P; Pitt B; Steg PG
    J Am Coll Cardiol; 2023 Nov; 82(19):1842-1851. PubMed ID: 37914514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
    Pérez MS; Rodríguez-Capitán J; Requena-Ibáñez JA; Santos-Gallego CG; Urooj Zafar M; Escolar G; Mancini D; Mitter S; Lam D; Contreras JP; Fergus I; Atallah-Lajam F; Abascal V; Lala A; Moreno P; Moss N; Lerakis S; Sanz J; Fuster V; Badimon JJ
    Cardiovasc Drugs Ther; 2023 Jun; ():. PubMed ID: 37318685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Clin Drug Investig; 2020 Jul; 40(7):665-669. PubMed ID: 32449083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
    N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin versus empagliflozin in patients with chronic kidney disease.
    Alnsasra H; Tsaban G; Solomon A; Khalil F; Aboalhasan E; Azab AN; Azuri J; Hammerman A; Arbel R
    Front Pharmacol; 2023; 14():1227199. PubMed ID: 37601066
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.